Immunotherapy May Improve mRCC Outcomes
SAN FRANCISCO—An immunotherapy (AGS-003) in combination with sunitinib may help prolong the lives of men with unfavorable risk, metastatic renal cell carcinoma (mRCC), according to new data from an open-label phase 2 study.